COMMUNIQUÉS West-GlobeNewswire

HealthLynked Announces Exciting New Update with HealthLynked 3.2.0 - Transforming Patient-Care Through Innovation
26/03/2024
NAPLES, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a pioneering healthcare network focused on enhancing the efficiency and quality of patient care, is thrilled to announce the [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26/03/2024
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best [...]
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
26/03/2024
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation [...]
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26/03/2024
Data readout from Phase 3 clinical trial in the People's Republic of China ( “ PRC ”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating [...]
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
26/03/2024
STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major [...]
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
26/03/2024
First in human phase I clinical study using OMV as an adjuvant for intranasal vaccination Avacc 10 ® intranasal booster vaccine induces a mucosal response and no adverse events Data will be presented at the World [...]
Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of Incorporation
26/03/2024
Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of Incorporation Monica Manotas proposed as a new member of the Board of [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
26/03/2024
PRESS RELEASE REGULATED INFORMATION 26 March 2024, 07:00 a.m. CET Ghent, Belgium, 26 March 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of [...]
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
26/03/2024
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, 2024 7:00 AM [...]
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
26/03/2024
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and [...]
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika
26/03/2024
Saint-Herblain (France), le 26 mars 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui l’initiation d’un essai de Phase 1 pour évaluer l’innocuité et l’ [...]
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion
26/03/2024
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion Clermont-Ferrand, France, Tuesday 26 March 2024 (06.45am CET) CARBIOS (Euronext Growth Paris: ALCRB), a [...]
CARBIOS rejoint Paris Good Fashion pour accélérer la circularité des textiles et contribuer à une mode plus durable
26/03/2024
CARBIOS rejoint Paris Good Fashion pour accélérer la circularité des textiles et contribuer à une mode plus durable Clermont-Ferrand (France), le mardi 26 mars 2024 (06h45 CET). CARBIOS , (Euronext Growth Paris : ALCRB [...]
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
26/03/2024
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company [...]
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25/03/2024
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured [...]
Precipio Announces Year end 2023 Shareholder Update Call
25/03/2024
Conference Call to be held on April 1st, 2024 at 5:00 PM EDT NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its year end 2023 [...]
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
25/03/2024
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12 th participant on March 23, 2024, in the Company’s ongoing Phase 2 [...]
Ibogaine By David Dardashti Explains the Legal Status of Ibogaine
25/03/2024
Ibogaine Therapy Provides an Effective Cure for Opiate Addiction MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Ibogaine by David Dardashti is proud to announce more information about the legal status of ibogaine in Mexico [...]
Goodness Growth Holdings Reschedules Fourth Quarter and Full Year 2023 Results Call to April 1, 2024
25/03/2024
MINNEAPOLIS, March 25, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and [...]

Pages